Immunocore Holdings (IMCR) Cash from Operations (2021 - 2026)
Immunocore Holdings (IMCR) posted Cash from Operations of 13775000.0 for Q1 2026, up 57.82% sequentially from 32655000.0 in Q4 2025, and down 3266.67% YoY from 435000.0 in Q1 2025.
Immunocore Holdings (IMCR) Cash from Operations (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported Cash from Operations for 6 years, with the latest figure at 13775000.0 in Q1 2026.
- Quarterly Cash from Operations fell 3266.67% year-over-year to 13775000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24922000.0 (down 180.18% YoY) and the FY2025 annual result came in at 10712000.0, down 141.1% from the prior year.
- Cash from Operations climbed to 13775000.0 in Q1 2026 per IMCR's latest filing, from 32655000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 25964000.0 in Q2 2025 and troughed at 32655000.0 in Q4 2025.
- A 5-year average of 1408551.57 and a median of 435000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2026: Cash from Operations jumped 52060.0% in 2024, then tumbled 3266.67% in 2026.
- Over 5 years, Cash from Operations stood at 7075103.63 in 2022, then slumped by 350.64% to 17733000.0 in 2023, then climbed by 21.33% to 13951000.0 in 2024, then plunged by 134.07% to 32655000.0 in 2025, then jumped by 57.82% to 13775000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 13775000.0, 32655000.0, and 4456000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Immunocore Holdings | 1.76 Bn | 880.92 Mn | 114.84 Mn | 15.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.93 Mn |
| Jun 30, 2026 | 15.93 Mn |
| Mar 31, 2026 | -13.78 Mn |
| Mar 31, 2026 | -13.78 Mn |
| Dec 31, 2025 | -32.66 Mn |
| Dec 31, 2025 | -32.66 Mn |
| Sep 30, 2025 | -4.46 Mn |
| Sep 30, 2025 | -4.46 Mn |
| Jun 30, 2025 | 25.96 Mn |
| Jun 30, 2025 | 25.96 Mn |
| Mar 31, 2025 | 435,000.00 |
| Mar 31, 2025 | 435,000.00 |
| Dec 31, 2024 | -13.95 Mn |
| Dec 31, 2024 | -13.95 Mn |
| Sep 30, 2024 | 21.13 Mn |
| Sep 30, 2024 | 21.13 Mn |
| Jun 30, 2024 | 23.47 Mn |
| Jun 30, 2024 | 23.47 Mn |
| Mar 31, 2024 | -4.59 Mn |
| Mar 31, 2024 | -4.59 Mn |